Clinical Trials

Trial Portfolio

Targeting approximately 30,000 patients over the next 3–4 years across oesophageal, gastric, pancreatic, liver and colorectal cancers.

Active
PANACEA
PAN Alimentary Cancer Exhaled breath Analysis

Multi-GI (Oesophageal, Gastric, Pancreatic, Liver, Colorectal)
Active
AROMA
Augmented Response of VOlatile BioMarkers in the Assessment of Oesophagogastric Adenocarcinoma

Oesophagogastric
Active
VAPOR
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma

Pancreatic
Active
COBRA
COlorectal BReath Analysis

Colorectal
Active
VOCAL
Volatile Organic Compound Assessment of Liver disease

Liver (HCC & Cholangiocarcinoma)
Active
ViSON
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Oesophageal Squamous Cell Carcinoma (OSCC)
Active
VIBES
Volatile Non-Invasive Biomarkers of Epileptic Seizures

Epilepsy (Neurological)
Active
HYDRA
HYpoxia Driven metabolic Response in esophagogastric Adenocarcinoma

Oesophagogastric
Complete
NEED
Non-Invasive Testing for Early Oesophageal Cancer and Dysplasia

Oesophageal Adenocarcinoma & Dysplasia
Complete
eDIGEST
Early diagnosis of upper DIGESTive tract disease

Upper Digestive Tract (OAC, OSCC, HNSCC)
Complete
MAPLES
Profiling Microbiome Associated Metabolic Pathways in Oesophageal Cancer Survivors

Oesophageal (Survivorship)
Complete
SEATTLE
Temporal variation in exhaled VOCs in response to therapeutic intervention in oesophageal cancer patients

Oesophageal
Complete
PANORAMA
Parkinson's Non-Invasive Volatile Organic Compound Analysis and Microbiome Assessment

Parkinson's Disease (Neurodegenerative)
Complete
AVOCADO
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma from the Tumour Lipidome

Oesophagogastric
Complete
HOPE
HOspital versus Primary care breath test Environment study

Cross-cutting (Methodological)